Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?

28 August 2016 (13:25 - 13:40)

Organised by:

About the speaker

Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

Introduction - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Doctor D. Fitchett (Toronto, CA)

Presentation thumbnail

Challenging CV Risk in diabetes: ready for a new approach?

Professor J. Deanfield (London, GB)

Presentation thumbnail

SGLT-2 inhibitors in T2DM management: current position & future promise.

Professor S. Inzucchi (New Haven, US)

Presentation thumbnail

Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Doctor D. Fitchett (Toronto, CA) Professor J. McMurray (Glasgow, GB)

Access the full session

Session thumbnail

SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

The Event

ESC Congress 2016

28 August 2016 13:25 CET

You may be interested in

Congress Presentation

Improving management of heart failure with reduced ejection fraction with sglt2i's by exploring practical considerations: an online education intervention

27 August 2021

Congress Session

Novel therapies in managing patients with cardiovascular-kidney-metabolic (CKM) syndrome and heart failure

4 April 2025

Webinar

Clinical trials and highlights from ACC 2024

10 April 2024

Congress Presentation

The renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure (RECEDE-CHF) trial

30 August 2020

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources